BDX Introduces BD Research Cloud 7.0 for Advanced Flow Cytometry

Becton, Dickinson and Company BDX, popularly known as BD, recently announced the global commercial launch of BD Research Cloud 7.0, marking another step forward in its AI-driven life sciences strategy. The latest upgrade strengthens BD’s position in flow cytometry by integrating advanced automation and data intelligence aimed at improving research quality and productivity.

The highlight of the release is BD Horizon Panel Maker, an AI-powered tool designed to simplify and optimize experimental panel design in immunology and cancer research.

Likely Trend of BDX Stock Following the News

Following the announcement, the company's shares traded flat at yesterday’s closing. In the last six-month period, shares have gained 11.2% against the industry’s 11.5% decline. The S&P 500 has gained 10.8% in the same time frame.

Over the long term, the launch of BD Research Cloud 7.0 is likely to strengthen BDX’s business by deepening customer lock-in, driving higher utilization of its flow cytometry instruments, and expanding recurring software and consumables revenue. By embedding AI directly into critical research workflows, BD enhances switching costs, improves customer productivity, and differentiates its ecosystem beyond hardware, supporting more stable margins and sustained growth as life sciences labs increasingly prioritize automation, data quality, and integrated digital platforms.

BDX currently has a market capitalization of $57.49 billion.

More on the News

BD Research Cloud version 7.0 delivers a cloud-based flow cytometry ecosystem designed to improve collaboration, streamline end-to-end workflows and support day-to-day laboratory operations. The platform enables researchers to manage key functions ranging from instrument health monitoring to reagent purchasing and inventory management, helping labs operate more efficiently while maintaining consistency across teams and experiments.

A core enhancement in the release is the BD Horizon Panel Maker, which uses an advanced AI algorithm to generate optimized panel recommendations within seconds. Researchers can design panels using custom experimental inputs or select from curated databases of validated options, reducing the risk of poorly designed panels that can lead to unusable or irreproducible data.

The tool also includes integrated visualization features such as comparison tables and complexity scores, allowing faster and more informed panel selection. In addition, the software is designed to fully support advanced imaging and spectral panel design when used with BD FACSDiscover Cell Analyzers and Cell Sorters, maximizing the performance of both BD’s hardware and software platforms.

Favorable Industry Prospect for BDX

Per a report by Grand View Research, the global flow cytometry market size was estimated at $4.68 billion in 2024 and is projected to reach $7.01 million by 2030, expanding at a CAGR of 8.41% from 2025 to 2030.

The increasing incidence of cancer, immunodeficiency disorders and infectious diseases is a key factor propelling market growth.

A Recent Development by BDX

BDX recently announced the expansion of its partnership with Ypsomed to develop a 5.5 mL version of the BD Neopak XtraFlow Glass Prefillable Syringe. BD and Ypsomed have a long-standing partnership that began with the BD Neopak XtraFlow 2.25 mL Glass Prefillable Syringe and the YpsoMate 2.25 autoinjector that delivered improved flow and faster injection times across multiple drug viscosities.

BDX’s Zacks Rank & Other Key Picks

Currently, BDX carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks in the broader medical space are IDEXX Laboratories IDXX, Boston Scientific BSX and STERIS STE. Each stock presently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Estimates for IDEXX’s 2025 earnings per share (EPS) have remained constant at $12.93 in the past 30 days. Shares of the company have risen 12.6% in the past year compared with the industry’s 11.1% growth. IDXX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.1%. In the last reported quarter, it delivered an earnings surprise of 8.3%.  

Boston Scientific shares have gained 2.9% in the past year. Estimates for the company’s 2025 EPS have remained constant at $3.04 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.4%. In the last reported quarter, it posted an earnings surprise of 5.6%.

STERIS shares have risen 9.1% in the past year. Estimates for the company’s 2025 EPS have increased by 2 cents to $10.23 in the past 30 days. STE’s earnings topped estimates in three of the trailing four quarters and matched on one occasion, delivering an average surprise of 2.6%. In the last reported quarter, it posted an earnings surprise of 2.6%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research